This latest edition of the Health Products Regulatory Authority (HPRA) Drug Safety Newsletter includes recommendations and advice issued by the European Medicines Agency's (EMA's) safety committee (the PRAC) to healthcare professionals on a small number of very rare but important adverse reactions associated with Covid-19 vaccines.

The 104th edition includes:

• Covid-19 Vaccines Pharmacovigilance Update
• Myocarditis and pericarditis – Comirnaty® and Spikevax®
• Thrombosis with thrombocytopenia syndrome (TTS) – Vaxzevria® and Covid-19 Vaccine Janssen®
• Capillary Leak Syndrome – Vaxzevria® and Covid-19 Vaccine Janssen®
• Guillain-Barré Syndrome (GBS) – Vaxzevria® and Covid-19 Vaccine Janssen®
• Direct Healthcare Professional Communications published on the HPRA website since the last update

For further details please click here.